Aficamten improves peak oxygen uptake in obstructive HCM

Name: Aficamten improves peak oxygen uptake in obstructive HCM
Uploaded: 2024-07-02T06:00:00+00:00
Description: Aficamten is a novel cardiac myosin inhibitor that targets hypercontractility in patients with obstructive HCM. Its effects were examined in the phase 3 SE

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Mavacamten in symptomatic non-obstructive HCM
Mavacamten in symptomatic non-obstructive HCM
ESC Congress 2025
Mavacamten in symptomatic non-obstructive HCM
- Milind Desai, MD
First ESC guidelines on cardiomyopathies - diagnosis
First ESC guidelines on cardiomyopathies - diagnosis
ESC Congress 2023
First ESC guidelines on cardiomyopathies - diagnosis
- Elena Arbelo, MD, PhD
First ESC guidelines on cardiomyopathies - management
First ESC guidelines on cardiomyopathies - management
ESC Congress 2023
First ESC guidelines on cardiomyopathies - management
- Juan Pablo Kaski, MD
Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape?
Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape?
Innovative therapeutic approaches in hypertrophic cardiomyopathy
Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape?
- Prof. Iacopo Olivotto, MD

Aficamten improves peak oxygen uptake in obstructive HCM

Recommended

Title

Share on ReachMD